Cargando…

Brazilian guidelines for diagnosis, treatment and follow-up of primary cutaneous melanoma - Part II

The last Brazilian guidelines on melanoma were published in 2002. Development in diagnosis and treatment made updating necessary. The coordinators elaborated ten clinical questions, based on PICO system. A Medline search, according to specific MeSH terms for each of the 10 questions was performed an...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Luiz Guilherme Martins, Bakos, Renato Marchiori, Duprat Neto, João Pedreira, Bittencourt, Flávia Vasques, Giacomo, Thais Helena Bello Di, Serpa, Sérgio Schrader, Messina, Maria Cristina de Lorenzo, Loureiro, Walter Refkalefsky, Macarenco, Ricardo Silvestre e Silva, Stolf, Hamilton Ometto, Gontijo, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782647/
https://www.ncbi.nlm.nih.gov/pubmed/26982779
http://dx.doi.org/10.1590/abd1806-4841.20164715
Descripción
Sumario:The last Brazilian guidelines on melanoma were published in 2002. Development in diagnosis and treatment made updating necessary. The coordinators elaborated ten clinical questions, based on PICO system. A Medline search, according to specific MeSH terms for each of the 10 questions was performed and articles selected were classified from A to D according to level of scientific evidence. Based on the results, recommendations were defined and classified according to scientific strength. The present Guidelines were divided in two parts for editorial and publication reasons. In this second part, the following clinical questions were answered: 1) which patients with primary cutaneous melanoma benefit from sentinel lymph node biopsy? 2) Follow-up with body mapping is indicated for which patients? 3) Is preventive excision of acral nevi beneficious to patients? 4) Is preventive excision of giant congenital nevi beneficious to patients? 5) How should stages 0 and I primary cutaneous melanoma patients be followed?